Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 September 2022 | Story Edzani Nephalela | Photo Edzani Nephalela
Jerry Thoka
Swanti Jerry Thoka, former CSRC President and Actuarial Science student, expresses his questions and policy proposals during the questions-and-answers session.

Multilingualism is a buzzword at many South African universities. These universities promote social cohesion, a sense of belonging, and epistemic access and success by improving and advancing existing language policies and practices.

On 16 September 2022, the University of the Free State (UFS) had its first student discussion on the Bloemfontein Campus regarding the draft Language Policy, which is being reviewed for an updated version in 2023. With English being the primary language of teaching and learning, this policy aims to promote diversity in teaching and learning in Sesotho, isiZulu, Afrikaans, and Sign Language through translating tutorials and academic vocabulary and continuously establishing and maintaining trans-institutional, interinstitutional, and intra-institutional collaborations for the development of a translanguaging culture.

During the presentation, Dr Nomalungelo Ngubane, Director of the Academy for Multilingualism, revealed to students that the United Nations Educational, Scientific and Cultural Organisation (UNESCO) has designated a decade – from 2022 to 2032 – as the International Decade of Indigenous Languages. This guarantees that these languages are promoted and advanced enough to be utilised as academic languages in academia. "This puts pressure on the Department of Higher Education and Training (DHET) to recognise students' different languages in institutions. Section 29 of the South African Constitution further stipulates that we all have the right to learn in our preferred language, but only if it is practical. So currently, we cannot learn in these languages due to the lack of glossaries," Dr Ngubane said.

During the question-and-answer session, Swanti Jerry Thoka, a former Campus Student Representative Council (CSRC) President and Actuarial Science student, cited the policy. "The policy states that it will entail developing previously disadvantaged languages, which includes both indigenous languages and Sign Language, as well as continuing to improve existing ones. Why don't we concentrate on development because the current languages have advanced? For example, a Sign Language policy appears to exist, but it lacks a comprehensive execution strategy," Thoka said. 

Dr Ngubane noted all the remarks and questions, and assured attendees that they would be addressed at the next Council meeting. She stressed the value of students’ participation in policymaking, since their future is being debated. She further explained that students should provide the SRC with recommendations to submit at the Council meetings, because the SRC are their elected representatives.


Dr Nomalungelo Ngubane, Director of the Academy for Multilingualism, presents the draft language policy at the Equitas, Bloemfontein Campus.
(Photo: Edzani Nephalela) 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept